- Home
- GNLX
GNLX
Genelux Corporation
as 12-20-2024 4:00pm EST
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 103.6M | IPO Year: | 2023 |
| Target Price: | $18.25 | AVG Volume (30 days): | 142.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $16.60 | Next Earning Date: | 11-14-2024 |
| Revenue: | $8,000 | Revenue Growth: | -96.64% |
| Revenue Growth (this year): | -97.6% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Genelux Corporation (GNLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zindrick Thomas | GNLX | President and CEO | Dec 16 '24 | Sell | $2.34 | 14,315 | $33,497.10 | 37,372 | |
| Zak Lourie S. | GNLX | Chief Financial Officer | Dec 16 '24 | Sell | $2.34 | 2,103 | $4,921.02 | 40,802 | |
| Smalling Ralph | GNLX | Head of Regulatory | Dec 16 '24 | Sell | $2.34 | 2,510 | $5,873.40 | 16,322 | |
| Cappello Joseph | GNLX | VP, Pharmaceutical Development | Dec 16 '24 | Sell | $2.34 | 6,300 | $14,742.00 | 14,653 |
Latest Genelux Corporation News
GNLX Breaking Stock News: Dive into GNLX Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
TipRanks
a month ago
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
GlobeNewswire
a month ago
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
GlobeNewswire
a month ago
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
Simply Wall St.
2 months ago
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well
MT Newswires
2 months ago
Guggenheim Initiates Genelux at Buy With $8 Price Target
GuruFocus.com
2 months ago
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp
Clinical Trials Arena
2 months ago
Genelux doses first subject in Phase II trial of NSCLC treatment
Compare GNLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNLX Genelux Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.